Patronus Biotech Begins Clinical Trial for Malaria Vaccine Candidates

GUANGZHOU, China, Oct. 20, 2026 /CourierPR/ -- Patronus Biotech, a biotechnology company that develops next-generation vaccines to address unmet global needs, has received ethical approval for its first-in-human Phase 1 clinical trial of three novel multi-stage virus-like-particle (VLP)-based investigational vaccine candidates against malaria. The trial, NCT07831226, is set to begin in Australia, with the Bellberry Limited Research Ethics Committee providing the necessary approval on October 19, 2026.

The clinical trial will evaluate the safety and immunogenicity of three vaccine candidates: LYB014, LYB017, and LYB027. LYB014 targets three key stages of the Plasmodium falciparum malaria parasite lifecycle, while LYB017 targets three key stages of the Plasmodium vivax malaria parasite lifecycle. LYB027, the most advanced of the three, targets these three key life stages of both the P. falciparum and P. vivax lifecycles. These vaccines will be administered with the proprietary A02 adjuvant, a novel liposomal adjuvant containing fully synthetic active ingredients.

The clinical trial will be conducted at Nucleus Network Pty Ltd. in Melbourne, Australia, with the first participant enrolment expected in December 2026. The immunogenicity analysis for the trial will be conducted in collaboration with the Draper Lab, based at the Department of Paediatrics at the University of Oxford.

Patronus Biotech's vaccine candidates are designed to address the need for a next-generation vaccine for malaria that can target the three key stages of the malaria life cycle, with the ambition of contributing to future efforts to eliminate malaria by preventing infection, disease, and transmission. Despite significant progress, malaria remains a major global health threat, causing an estimated 282 million cases and 610,000 deaths worldwide in 2024. The two key malaria species, P. falciparum and P. vivax, have complex life cycles beginning with sporozoites transmitted by the bite of an infected mosquito, where they travel to the liver, and then emerge into the bloodstream where they invade and replicate within red blood cells. A portion of these parasites become the sexual-stage, which is then taken up by another mosquito, allowing the lifecycle to progress and enabling transmission to the next person.

The current WHO-approved RTS,S/AS01 and R21/Matrix-M vaccines target the first stage of the P. falciparum parasite lifecycle only and demonstrated partial efficacy against clinical malaria in previous Phase 2/3 field trials in pediatric populations. The new vaccines, LYB014, LYB017, and LYB027, are designed to test whether additional targeting of the remaining stages of the life-cycle and/or targeting multiple parasite species can provide complementary, layered protection, a hypothesis that will be assessed in future efficacy trials.

Patronus Biotech is a biotechnology company that develops next-generation vaccines to address unmet global needs. The company's vaccine candidates are designed to target the three key stages of the malaria life cycle, with the ambition of contributing to future efforts to eliminate malaria by preventing infection, disease, and transmission. Despite significant progress, malaria remains a major global health threat, causing an estimated 282 million cases and 610,000 deaths worldwide in 2024. The two key malaria species, P. falciparum and P. vivax, have complex life cycles beginning with sporozoites transmitted by the bite of an infected mosquito, where they travel to the liver, and then emerge into the bloodstream where they invade and replicate within red blood cells. A portion of these parasites become the sexual-stage, which is then taken up by another mosquito, allowing the lifecycle to progress and enabling transmission to the next person.

The current WHO-approved RTS,S/AS01 and R21/Matrix-M vaccines target the first stage of the P. falciparum parasite lifecycle only and demonstrated partial efficacy against clinical malaria in previous Phase 2/3 field trials in pediatric populations. The new vaccines, LYB014, LYB017, and LYB027, are designed to test whether additional targeting of the remaining stages of the life-cycle and/or targeting multiple parasite species can provide complementary, layered protection, a hypothesis that will be assessed in future efficacy trials.